Octreotide acetate 20mg
Product Overview
| Generic Name | Octreotide acetate 20mg |
| Brand Name(s) | Sandostatin® LAR Depot |
| Category | Antineoplastic / Cancer |
| Form | Powder and solvent for prolonged-release injectable suspension; IM depot/LAR. |
| Strength | 20 mg vial/kit |
| Therapeutic Class | Somatostatin analogue |
| ATC Code | H01CB02 |
Manufacturing & Regulatory
| Manufacturer | Novartis, Teva |
| GMP Compliance | WHO-GMP |
| COFEPRIS | 010.000.5171 |
| Free Sale Certificate | Yes, available as COPP/CPP |
Logistics & Export
| MOQ | 10 Units |
| Shelf Life | 24 Months |
| Storage | 2–8 °C, protect from light |
| Incoterms | EXW, HSN 30049099 |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Supplied per batch upon request |
| CTD Summary (PDF) | CTD available to regulators; summary available to qualified partners |
Special Notes
Octreotide LAR is a long-acting somatostatin analogue used for acromegaly and for long-term control of severe diarrhea/flushing from metastatic carcinoid tumors and profuse watery diarrhea from VIP-secreting tumors, after the patient has responded to and tolerated short-acting octreotide.